The arrest of two former officials from Argentina’s National Administration of Foods, Medicaments and Medical Technology (ANMAT) has intensified scrutiny over the agency’s role in allowing contaminated fentanyl vials to reach 54 hospitals and clinics across the country. The investigation into potential regulatory failures linked to HLB Pharma and Laboratorios Ramallo, two companies responsible for producing and distributing non-compliant fentanyl, has uncovered evidence suggesting a systemic failure to enforce safety protocols. According to documents filed with Judge Ernesto Kreplak of La Plata, prosecutors allege that both officials, Nélida Agustina Bisio and Gabriela Mantecón Fumadó, deliberately delayed or ignored measures that could have prevented deaths caused by the tainted drug. The case, which dates back more than a year, has gathered additional weight as new evidence points to a “state cover-up,” according to the Ministry of Public Prosecution. The charges against Bisio, who served as national administrator of ANMAT until January this year, and Mantecón Fumadó, former head of the National Institute of Medicines (Iname) until August last year, include allegations that they maintained private communication channels with laboratory executives, thereby influencing decisions and concealing information about inspections. Prosecutors claim that these officials failed to act on warnings dating back to 2023, despite internal reports highlighting health risks. One key piece of evidence involves the deletion of WhatsApp messages by Mantecón Fumadó shortly before she left her post, raising concerns about the suppression of critical data. Additionally, while technical departments within Iname had requested action against HLB Pharma, the process was stalled for 38 days under Bisio’s leadership, allowing the distribution of potentially lethal medication to continue unchecked. This is not the first time ANMAT has faced criticism for its regulatory oversight. Over its 34 years of operation, the agency has been implicated in several high-profile cases, including the unauthorized importation of ephedrine far exceeding domestic production needs, and the accumulation of unresolved files involving laboratories operating outside legal guidelines. Its performance in food safety monitoring has also come under fire, particularly following the dissolution of the National Institute of Food (INAL) earlier this week. During the pandemic, decisions regarding vaccine approvals, such as the emergency authorization of Sinopharm for children aged three to 11, were criticized for lacking scientific rigor and being influenced by political considerations rather than public health priorities. The recent scandal surrounding the contaminated fentanyl has further exposed weaknesses in the agency’s ability to safeguard public health. Despite multiple inspections and alerts issued by internal teams, the public warning came only four months after the initial discovery of the issue. The delay allowed the affected drugs to circulate widely, resulting in 90 confirmed deaths and 41 severe injuries. Investigators have found that the conditions within the HLB Pharma facility were substandard, with workers reportedly entering the lab in underwear and leaving doors open, creating an environment conducive to contamination. A former employee described how staff knew the product was compromised but did not take corrective actions, indicating a culture of negligence or complicity. Prosecutors argue that the broader implications extend beyond individual misconduct, pointing to structural flaws within ANMAT and possible collusion with powerful industry interests. The term “state cover-up” has emerged as a central accusation, suggesting that regulatory decisions were influenced by external pressures rather than adherence to medical standards. This has raised questions about the independence of the agency and its capacity to function as a true watchdog. The ongoing investigation continues to uncover new layers of complexity, with the possibility of implicating higher-ranking officials, including past and current ministers of health. As the case unfolds, the focus remains on determining whether the failures were isolated incidents or part of a larger pattern of institutional corruption.
★
Keep the news honest.
ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €4/month.
Become a Supporter
AR
